At the close, Yimingang-B (01541) surged more than 17%, rising 11.5% to HKD 16.1 with a turnover of HKD 4.9677 million as of the time of publishing.
According to the Wise Money APP, Yimingang-B (01541) soared more than 17% at the close, rising 11.5% to HKD 16.1 with a turnover of HKD 4.9677 million as of the time of publishing.
On the news front, Yimingang recently announced that it has been approved by the Chinese National Medical Products Administration's Center for Drug Evaluation to conduct the Phase III clinical trial program of its core product, IMM01 (Timdapexip) combined with azathioprine, for first-line treatment of chronic myelomonocytic leukemia (CMML). It is reported that this product is China's first SIRPα-Fc fusion protein to enter clinical stage.
In addition, Yimingang recently presented two Phase II clinical data on its core product, Timdapexip (IMM01), at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.